Tumor homing peptides as molecular probes for cancer therapeutics, diagnostics and theranostics

Current Medicinal Chemistry

Volumn 21, Issue 21, 2014, Pages 2367-2391

  Gautam, A ^a   Kapoor, P ^a   Chaudhary, K ^a   Kumar, R ^a   Raghava, G P S ^a  

^a INSTITUTE OF MICROBIAL TECHNOLOGY   (India)

Author keywords

Cancer therapeutics; Cytotoxicity; Diagnostics; Multifunctional nanoparticle; Targeted drug delivery; Theranostics; Tumor homing peptides; Tumor vasculature

Indexed keywords

ACTINIUM 225; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; BISMUTH 213; CILENGITIDE; DIPHTHERIA TOXIN; DOXORUBICIN; FIRTECAN; GAMMA INTERFERON; INTERLEUKIN 12; LIPOSOME; MACROGOL; NANOPARTICLE; OLIGONUCLEOTIDE; PACLITAXEL; PEPTIDE; PLASMID DNA; POLYMER; PROTEIN P53; QUANTUM DOT; RADIOISOTOPE; SMALL INTERFERING RNA; TACHYPLESIN; TOXIC SHOCK SYNDROME TOXIN 1; TUMOR HOMING PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR PENETRATING PEPTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2 ANTAGONIST; MOLECULAR PROBE;

AMINO ACID SEQUENCE; ARTICLE; BLADDER CARCINOMA; BREAST CANCER; BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER THERANOSTICS; CANCER THERAPY; COLON CARCINOMA; COLORECTAL CANCER; COMBINATORIAL LIBRARY; DRUG DELIVERY SYSTEM; DRUG SCREENING; ESOPHAGUS CANCER; EX VIVO STUDY; GLIOMA; HEAD AND NECK CARCINOMA; HUMAN; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG CARCINOMA; LYMPHOMA; MELANOMA; MICELLE; MOLECULAR PROBE; NASOPHARYNX CANCER; NASOPHARYNX CARCINOMA; NEUROBLASTOMA; NONHUMAN; ONE BEAD ONE COMPOUND LIBRARY; OVARY CANCER; PANCREAS CARCINOMA; PEPTIDE LIBRARY; PHAGE DISPLAY; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; TUMOR VASCULARIZATION; ANIMAL; CLINICAL TRIAL (TOPIC); DRUG DESIGN; METABOLISM; NEOPLASMS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; HUMANS; MOLECULAR PROBES; NEOPLASMS; PEPTIDES;

EID: 84901949675     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666140217122100     Document Type: Article

References (216)

1. Ruoslahti, E. Specialization of tumour vasculature. Nat. Rev. Cancer, 2002, 2, 83-90. (Pubitemid 37328795)
2. Ruoslahti, E.; Rajotte, D. An address system in the vasculature of normal tissues and tumors. Annal. Rev. Immunol., 2000, 18, 813-827.
3. Joyce, J. A.; Laakkonen, P.; Bernasconi, M.; Bergers, G.; Ruoslahti, E.; Hanahan, D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell., 2003, 4, 393-403.
4. Hoffman, J. A.; Giraudo, E.; Singh, M.; Zhang, L.; Inoue, M.; Porkka, K.; Hanahan, D.; Ruoslahti, E. Progressive vascular changes in a transgenic mouse model of squamous cell carcinoma. Cancer Cell, 2003, 4, 383-391.
5. Ruoslahti, E. Vascular zip codes in angiogenesis and metastasis. Biochem. Soc. transact., 2004, 32, 397-402.
6. Deutscher, S. L. Phage display in molecular imaging and diagnosis of cancer. Chem. Rev., 2010, 110, 3196-3211.
7. Laakkonen, P.; Vuorinen, K. Homing peptides as targeted delivery vehicles. Integr. Biol. (Camb)., 2010, 2, 326-337.
8. Vlieghe, P.; Lisowski, V.; Martinez, J.; Khrestchatisky, M. Synthetic therapeutic peptides: science and market. Drug Discov. Today, 2010, 15, 40-56.
9. Craik, D. J.; Fairlie, D. P.; Liras, S.; Price, D. The future of peptide-based drugs. Chem. Biol. Drug Des., 2013, 81, 136-147.
10. Pasqualini, R.; Koivunen, E.; Ruoslahti, E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol., 1997, 15, 542-546.
11. Liu, Z.; Wu, K. Peptides homing to tumor vasculature: imaging and therapeutics for cancer. Recent Pat. Anticancer Drug Discov., 2008, 3, 202-208.
12. Weis, S. M.; Cheresh, D. A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med., 2011, 17, 1359-1370.
13. Li, Z. J.; Cho, C. H. Peptides as targeting probes against tumor vasculature for diagnosis and drug delivery. J. Transl. Med., 2012, 10 Suppl 1, S1.
14. Aina, O. H.; Liu, R.; Sutcliffe, J. L.; Marik, J.; Pan, C.-X.; Lam, K. S. From combinatorial chemistry to cancer-targeting peptides. Mol. Pharmaceut., 2007, 4, 631-651.
15. Azzazy, H. M. E.; Highsmith, W. E. Phage display technology: clinical applications and recent innovations. Clin. Biochem., 2002, 35, 425-445.
16. Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science (New York, N.Y.), 1985, 228, 1315-1317.
17. Samoylova, T. I.; Petrenko, V. A.; Morrison, N. E.; Globa, L. P.; Baker, H. J.; Cox, N. R. Phage probes for malignant glial cells. Mol. Cancer Therap., 2003, 2, 1129-1137.
18. McGuire, M. J.; Samli, K. N.; Chang, Y.-C.; Brown, K. C. Novel ligands for cancer diagnosis: selection of peptide ligands for identification and isolation of B-cell lymphomas. Exp. Hematol., 2006, 34, 443-452.
19. Kolonin, M. G.; Bover, L.; Sun, J.; Zurita, A. J.; Do, K.-A.; Lahdenranta, J.; Cardó-Vila, M.; Giordano, R. J.; Jaalouk, D. E.; Ozawa, M. G.; Moya, C. A.; Souza, G. R.; Staquicini, F. I.; Kunyiasu, A.; Scudiero, D. A.; Holbeck, S. L.; Sausville, E. A.; Arap, W.; Pasqualini, R. Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries. Cancer Res., 2006, 66, 34-40.
20. Zhang, Y.; Chen, J.; Zhang, Y.; Hu, Z.; Hu, D.; Pan, Y.; Ou, S.; Liu, G.; Yin, X.; Zhao, J.; Ren, L.; Wang, J. Panning and identification of a colon tumor binding peptide from a phage display peptide library. J. Biomol. Screen., 2007, 12, 429-435.
21. Zhang, B.; Zhang, Y.; Wang, J.; Zhang, Y.; Chen, J.; Pan, Y.; Ren, L.; Hu, Z.; Zhao, J.; Liao, M.; Wang, S. Screening and identification of a targeting peptide to hepatocarcinoma from a phage display peptide library. Mol. Med., 13, 246-254.
22. Zang, L.; Shi, L.; Guo, J.; Pan, Q.; Wu, W.; Pan, X.; Wang, J. Screening and identification of a peptide specifically targeted to NCI-H1299 from a phage display peptide library. Cancer Lett., 2009, 281, 64-70.
23. Porkka, K.; Laakkonen, P.; Hoffman, J. A.; Bernasconi, M.; Ruoslahti, E. A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc. Natl. Acad. Sci. USA, 2002, 99, 7444-7449.
24. Laakkonen, P.; Porkka, K.; Hoffman, J. A.; Ruoslahti, E. A tumorhoming peptide with a targeting specificity related to lymphatic vessels. Nat. Med., 2002, 8, 751-755.
25. Lam, K. S.; Salmon, S. E.; Hersh, E. M.; Hruby, V. J.; Kazmierski, W. M.; Knapp, R. J. A new type of synthetic peptide library for identifying ligand-binding activity. Nature, 1991, 354, 82-84.
26. Lam, K. S.; Lebl, M.; Krchnák, V. The "One-Bead-One- Compound" Combinatorial Library Method. Chem. Rev., 1997, 97, 411-448.
27. Pennington, M. E.; Lam, K. S.; Cress, A. E. The use of a combinatorial library method to isolate human tumor cell adhesion peptides. Mol. Divers., 1996, 2, 19-28.
28. Mikawa, M.; Wang, H.; Guo, L.; Liu, R.; Marik, J.; Takada, Y.; Lam, K.; Lau, D. Novel peptide ligands for integrin alpha 4 beta 1 overexpressed in cancer cells. Mol. Cancer Therap., 2004, 3, 1329-1334.
29. Aina, O. H.; Marik, J.; Liu, R.; Lau, D. H.; Lam, K. S. Identification of novel targeting peptides for human ovarian cancer cells using "one-bead one-compound" combinatorial libraries. Mol. Cancer Therap., 2005, 4, 806-813.
30. Zhang, H.; Aina, O. H.; Lam, K. S.; De Vere White, R.; Evans, C.; Henderson, P.; Lara, P. N.; Wang, X.; Bassuk, J. A.; Pan, C.-X. Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach. Urol. Oncol., 2012, 30, 635-645.
31. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 1996, 86, 353-364.
32. Folkman, J. Role of angiogenesis in tumor growth and metastasis. Semin. Oncol., 2002, 29, 15-18.
33. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science (New York, N.Y.), 1998, 279, 377-380.
34. Pasqualini, R.; Koivunen, E.; Kain, R.; Lahdenranta, J.; Sakamoto, M.; Stryhn, A.; Ashmun, R. A.; Shapiro, L. H.; Arap, W.; Ruoslahti, E. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res., 2000, 60, 722-727.
35. Desgrosellier, J. S.; Cheresh, D. A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. rev. Cancer, 2010, 10, 9-22.
36. Rangel, R.; Sun, Y.; Guzman-Rojas, L.; Ozawa, M. G.; Sun, J.; Giordano, R. J.; Van Pelt, C. S.; Tinkey, P. T.; Behringer, R. R.; Sidman, R. L.; Arap, W.; Pasqualini, R. Impaired angiogenesis in aminopeptidase N-null mice. Proc. Natl. Acad. Sci. USA, 2007, 104, 4588-4593.
37. Gaertner, F. C.; Kessler, H.; Wester, H.-J.; Schwaiger, M.; Beer, A. J. Radiolabelled RGD peptides for imaging and therapy. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39 Suppl 1, S126-S138.
38. Zou, M.; Zhang, L.; Xie, Y.; Xu, W. NGR-based strategies for targeting delivery of chemotherapeutics to tumor vasculature. Anti-Cancer Agents Med. Chem., 2012, 12, 239-246.
39. Zhang, L.; Giraudo, E.; Hoffman, J. A.; Hanahan, D.; Ruoslahti, E. Lymphatic zip codes in premalignant lesions and tumors. Cancer Res., 2006, 66, 5696-5706.
40. Laakkonen, P.; Zhang, L.; Ruoslahti, E. Peptide targeting of tumor lymph vessels. Ann. N. Y. Acad. Sci., 2008, 1131, 37-43.
41. Christian, S.; Pilch, J.; Akerman, M. E.; Porkka, K.; Laakkonen, P.; Ruoslahti, E. Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J. Cell Biol., 2003, 163, 871-878. (Pubitemid 37517893)
42. Fogal, V.; Zhang, L.; Krajewski, S.; Ruoslahti, E. Mitochondrial/cell- surface protein p32/gC1qR as a molecular target in tumor cells and tumor stroma. Cancer Res., 2008, 68, 7210-7218.
43. Rundhaug, J. E. Matrix metalloproteinases and angiogenesis. J. Cell Mol. Med., 2005, 9, 267-285.
44. Koivunen, E.; Arap, W.; Valtanen, H.; Rainisalo, A.; Medina, O. P.; Heikkilä, P.; Kantor, C.; Gahmberg, C. G.; Salo, T.; Konttinen, Y. T.; Sorsa, T.; Ruoslahti, E.; Pasqualini, R. Tumor targeting with a selective gelatinase inhibitor. Nat. Biotechnol., 1999, 17, 768-774.
45. Mueller, J.; Gaertner, F. C.; Blechert, B.; Janssen, K.-P.; Essler, M. Targeting of tumor blood vessels: a phage-displayed tumor-homing peptide specifically binds to matrix metalloproteinase-2-processed collagen IV and blocks angiogenesis in vivo. Mol. Cancer Res., 2009, 7, 1078-1085.
46. Pilch, J.; Brown, D. M.; Komatsu, M.; Järvinen, T. A. H.; Yang, M.; Peters, D.; Hoffman, R. M.; Ruoslahti, E. Peptides selected for binding to clotted plasma accumulate in tumor stroma and wounds. Proc. Natl. Acad. Sci. USA, 2006, 103, 2800-2804.
47. Yang, W.; Luo, D.; Wang, S.; Wang, R.; Chen, R.; Liu, Y.; Zhu, T.; Ma, X.; Liu, R.; Xu, G.; Meng, L.; Lu, Y.; Zhou, J.; Ma, D. TMTP1, a novel tumor-homing peptide specifically targeting metastasis. Clin. Cancer Res., 2008, 14, 5494-5502.
48. Xiao, M.; Hong, Z.; Sun, L.; Wu, Y.; Zhang, N.; Liu, Y.; Luo, D.; Zhou, J.; Li, C. TMTP1, a novel tumor-homing peptide, specifically targets hematological malignancies and their metastases. J. Huazhong Univ. Sci. Technolog. Med. Sci., 2011, 31, 608-613.
49. Hakomori, S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl. Acad. Sci. USA, 2002, 99, 10231-10233.
50. Hatakeyama, S.; Sugihara, K.; Shibata, T. K.; Nakayama, J.; Akama, T. O.; Tamura, N.; Wong, S.-M.; Bobkov, A. A.; Takano, Y.; Ohyama, C.; Fukuda, M.; Fukuda, M. N. Targeted drug delivery to tumor vasculature by a carbohydrate mimetic peptide. Proc. Natl. Acad. Sci. USA, 2011, 108, 19587-19592.
51. Lee, T.-Y.; Lin, C.-T.; Kuo, S.-Y.; Chang, D.-K.; Wu, H.-C. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res., 2007, 67, 10958-10965.
52. Liu, M.; Li, Y.; Lei, Y.; Wagner, E. A Potent Retro-Inverso Dpeptide for Simultaneous Targeting Angiogenic Blood Vasculature and Tumor Cells. Bioconjugate Chem., 2013, 24 (1), 133-143.
53. Chang, D.-K.; Lin, C.-T.; Wu, C.-H.; Wu, H.-C. A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer. PloS One, 2009, 4, e4171.
54. He, X.; Na, M.-H.; Kim, J.-S.; Lee, G.-Y.; Park, J. Y.; Hoffman, A. S.; Nam, J.-O.; Han, S.-E.; Sim, G. Y.; Oh, Y.-K.; Kim, I.-S.; Lee, B.-H. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor. Mol. Pharmaceut., 2011, 8, 430-438.
55. Koivistoinen, A.; Ilonen, I. I. K.; Punakivi, K.; Räsänen, J. V; Helin, H.; Sihvo, E. I.; Bergman, M.; Salo, J. A. A novel peptide (Thx) homing to non-small cell lung cancer identified by ex vivo phage display. Clin. Transl. Oncol., 2013, 15 (6), 492-498.
56. Zhi, M.; Wu, K.-C.; Dong, L.; Hao, Z.-M.; Deng, T.-Z.; Hong, L.; Liang, S.-H.; Zhao, P.-T.; Qiao, T.-D.; Wang, Y.; Xu, X.; Fan, D.-M. Characterization of a specific phage-displayed Peptide binding to vasculature of human gastric cancer. Cancer Biol. Ther., 2004, 3, 1232-1235.
57. Hu, S.; Guo, X.; Xie, H.; Du, Y.; Pan, Y.; Shi, Y.; Wang, J.; Hong, L.; Han, S.; Zhang, D.; Huang, D.; Zhang, K.; Bai, F.; Jiang, H.; Zhai, H.; Nie, Y.; Wu, K.; Fan, D. Phage display selection of peptides that inhibit metastasis ability of gastric cancer cells with high liver-metastatic potential. Biochem. Biophys. Res. Commun., 2006, 341, 964-972.
58. Liang, S.; Lin, T.; Ding, J.; Pan, Y.; Dang, D.; Guo, C.; Zhi, M.; Zhao, P.; Sun, L.; Hong, L.; Shi, Y.; Yao, L.; Liu, J.; Wu, K.; Fan, D. Screening and identification of vascular-endothelial-cell-specific binding peptide in gastric cancer. J. Mol. Med., 2006, 84, 764-773.
59. Zhang, W.-J.; Sui, Y.-X.; Budha, A.; Zheng, J.-B.; Sun, X.-J.; Hou, Y.-C.; Wang, T. D.; Lu, S.-Y. Affinity peptide developed by phage display selection for targeting gastric cancer. World J. Gastroenterol., 2012, 18, 2053-2060.
60. Zitzmann, S.; Mier, W.; Schad, A.; Kinscherf, R.; Askoxylakis, V.; Krämer, S.; Altmann, A.; Eisenhut, M.; Haberkorn, U. A new prostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy. Clin. Cancer Res., 2005, 11, 139-146.
61. Newton-Northup, J. R.; Figueroa, S. D.; Quinn, T. P.; Deutscher, S. L. Bifunctional phage-based pretargeted imaging of human prostate carcinoma. Nucl. Med. Biol., 2009, 36, 789-800.
62. Pluschke, G.; Vanek, M.; Evans, A.; Dittmar, T.; Schmid, P.; Itin, P.; Filardo, E. J.; Reisfeld, R. A. Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan. Proc. Natl. Acad. Sci. USA, 1996, 93, 9710-9715.
63. Stallcup, W. B.; Huang, F.-J. A role for the NG2 proteoglycan in glioma progression. Cell Adh. Migr., 2008, 2 (3), 192-201.
64. Burg, M. A.; Pasqualini, R.; Arap, W.; Ruoslahti, E.; Stallcup, W. B. NG2 proteoglycan-binding peptides target tumor neovasculature. Cancer Res., 1999, 59, 2869-2874.
65. Matsuo, A. L.; Juliano, M. A.; Figueiredo, C. R.; Batista, W. L.; Tanaka, A. S.; Travassos, L. R. A new phage-display tumorhoming peptide fused to antiangiogenic peptide generates a novel bioactive molecule with antimelanoma activity. Mol. Cancer Res., 2011, 9, 1471-1478.
66. Jiang, Y.-Q.; Wang, H.-R.; Li, H.-P.; Hao, H.-J.; Zheng, Y.-L.; Gu, J. Targeting of hepatoma cell and suppression of tumor growth by a novel 12mer peptide fused to superantigen TSST-1. Mol. Med., 2006, 12, 81-87.
67. Lo, A.; Lin, C.-T.; Wu, H.-C. Hepatocellular carcinoma cellspecific peptide ligand for targeted drug delivery. Mol. Cancer Therap., 2008, 7, 579-589.
68. Zhao, X.; Hu, J.; Huang, R.; Yang, L. Identification of one vasculature specific phage-displayed peptide in human colon cancer. J. Exp. Clin. Cancer Res., 2007, 26, 509-514.
69. Kelly, K. A.; Jones, D. A. Isolation of a colon tumor specific binding peptide using phage display selection. Neoplasia, 2003, 5, 437-444.
70. Li, Z. J.; Wu, W. K. K.; Ng, S. S. M.; Yu, L.; Li, H. T.; Wong, C. C. M.; Wu, Y. C.; Zhang, L.; Ren, S. X.; Sun, X. G.; Chan, K. M.; Cho, C. H. A novel peptide specifically targeting the vasculature of orthotopic colorectal cancer for imaging detection and drug delivery. J. Control. Release, 2010, 148, 292-302.
71. Lee, S.-M.; Lee, E.-J.; Hong, H.-Y.; Kwon, M.-K.; Kwon, T.-H.; Choi, J.-Y.; Park, R.-W.; Kwon, T.-G.; Yoo, E.-S.; Yoon, G.-S.; Kim, I.-S.; Ruoslahti, E.; Lee, B.-H. Targeting bladder tumor cells in vivo and in the urine with a peptide identified by phage display. Mol. Cancer Res., 2007, 5, 11-19.
72. Hong, F. D.; Clayman, G. L. Isolation of a peptide for targeted drug delivery into human head and neck solid tumors. Cancer Res., 2000, 60, 6551-6556.
73. Nothelfer, E.-M.; Zitzmann-Kolbe, S.; Garcia-Boy, R.; Krämer, S.; Herold-Mende, C.; Altmann, A.; Eisenhut, M.; Mier, W.; Haberkorn, U. Identification and characterization of a peptide with affinity to head and neck cancer. J. Nucl. Med., 2009, 50, 426-434.
74. Simberg, D.; Duza, T.; Park, J. H.; Essler, M.; Pilch, J.; Zhang, L.; Derfus, A. M.; Yang, M.; Hoffman, R. M.; Bhatia, S.; Sailor, M. J.; Ruoslahti, E. Biomimetic amplification of nanoparticle homing to tumors. Proc. Natl. Acad. Sci. USA, 2007, 104, 932-936.
75. Zhi, M.; Wu, K.; Hao, Z.; Guo, C.; Yao, J. Screening of specific binding peptide targeting blood vessel of human esophageal cancer in vivo in mice. Chinese Med. J., 2011, 124, 581-585.
76. Ho, I. A. W.; Lam, P. Y. P.; Hui, K. M. Identification and characterization of novel human glioma-specific peptides to potentiate tumor-specific gene delivery. Human Gene Ther., 2004, 15, 719-732.
77. Ho, I. A. W.; Hui, K. M.; Lam, P. Y. P. Isolation of peptide ligands that interact specifically with human glioma cells. Peptides, 2010, 31, 644-650.
78. Böckmann, M.; Drosten, M.; Pützer, B. M. Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma. J. Gene Med., 2005, 7, 179-188.
79. Böckmann, M.; Hilken, G.; Schmidt, A.; Cranston, A. N.; Tannapfel, A.; Drosten, M.; Frilling, A.; Ponder, B. A. J.; Pützer, B. M. Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection. Human Gene Ther., 2005, 16, 1267-1275.
80. Lee, T.-Y.; Wu, H.-C.; Tseng, Y.-L.; Lin, C.-T. A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res., 2004, 64, 8002-8008.
81. Jain, R. K. Transport of molecules in the tumor interstitium: a review. Cancer Res., 1987, 47, 3039-3051.
82. Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Girard, O. M.; Hanahan, D.; Mattrey, R. F.; Ruoslahti, E. Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell., 2009, 16, 510-520.
83. Alberici, L.; Roth, L.; Sugahara, K. N.; Agemy, L.; Kotamraju, V. R.; Teesalu, T.; Bordignon, C.; Traversari, C.; Rizzardi, G.-P.; Ruoslahti, E. De Novo Design of a Tumor-Penetrating Peptide. Cancer Res., 2013, 73 (2), 804-812.
84. Myrberg, H.; Zhang, L.; Mäe, M.; Langel, U. Design of a tumorhoming cell-penetrating peptide. Bioconjugate Chem., 2008, 19, 70-75.
85. Teesalu, T.; Sugahara, K. N.; Kotamraju, V. R.; Ruoslahti, E. Cend rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration. Proc. Natl. Acad. Sci. USA, 2009, 106, 16157-16162.
86. Staton, C. A.; Kumar, I.; Reed, M. W. R.; Brown, N. J. Neuropilins in physiological and pathological angiogenesis. J. Pathol., 2007, 212, 237-248.
87. Roth, L.; Agemy, L.; Kotamraju, V. R.; Braun, G.; Teesalu, T.; Sugahara, K. N.; Hamzah, J.; Ruoslahti, E. Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene, 2012, 31, 3754-3763.
88. Sugahara, K. N.; Teesalu, T.; Karmali, P. P.; Kotamraju, V. R.; Agemy, L.; Greenwald, D. R.; Ruoslahti, E. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science, 2010, 328, 1031-1035.
89. Arap, W.; Pasqualini, R.; Ruoslahti, E. Chemotherapy targeted to tumor vasculature. Curr. Opin. Oncol., 1998, 10, 560-565.
90. Papahadjopoulos, D.; Allen, T. M.; Gabizon, A.; Mayhew, E.; Matthay, K.; Huang, S. K.; Lee, K. D.; Woodle, M. C.; Lasic, D. D.; Redemann, C. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA, 1991, 88, 11460-11464.
91. Safra, T.; Muggia, F.; Jeffers, S.; Tsao-Wei, D. D.; Groshen, S.; Lyass, O.; Henderson, R.; Berry, G.; Gabizon, A. Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann. Oncol., 2000, 11, 1029-1033.
92. Vail, D. M.; Amantea, M. A.; Colbern, G. T.; Martin, F. J.; Hilger, R. A.; Working, P. K. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin. Oncol., 2004, 31, 16-35.
93. Orlowski, R. Z.; Nagler, A.; Sonneveld, P.; Bladé, J.; Hajek, R.; Spencer, A.; San Miguel, J.; Robak, T.; Dmoszynska, A.; Horvath, N.; Spicka, I.; Sutherland, H. J.; Suvorov, A. N.; Zhuang, S. H.; Parekh, T.; Xiu, L.; Yuan, Z.; Rackoff, W.; Harousseau, J.-L. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J. Clin. Oncol., 2007, 25, 3892-3901.
94. Zhang, Y.-F.; Wang, J.-C.; Bian, D.-Y.; Zhang, X.; Zhang, Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur. J. Pharm. Biopharm., 2010, 74, 467-473.
95. Xiong, X.-B.; Huang, Y.; Lu, W.-L.; Zhang, X.; Zhang, H.; Nagai, T.; Zhang, Q. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J. Control. Release, 2005, 107, 262-275.
96. Pastorino, F.; Brignole, C.; Marimpietri, D.; Cilli, M.; Gambini, C.; Ribatti, D.; Longhi, R.; Allen, T. M.; Corti, A.; Ponzoni, M. Vascular damage and anti-angiogenic effects of tumor vesseltargeted liposomal chemotherapy. Cancer Res., 2003, 63, 7400-7409.
97. Yan, Z.; Zhan, C.; Wen, Z.; Feng, L.; Wang, F.; Liu, Y.; Yang, X.; Dong, Q.; Liu, M.; Lu, W. LyP-1-conjugated doxorubicin-loaded liposomes suppress lymphatic metastasis by inhibiting lymph node metastases and destroying tumor lymphatics. Nanotechnology, 2011, 22, 415103.
98. Yan, Z.; Wang, F.; Wen, Z.; Zhan, C.; Feng, L.; Liu, Y.; Wei, X.; Xie, C.; Lu, W. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor. J. Control. Release, 2012, 157, 118-125.
99. Du, H.; Cui, C.; Wang, L.; Liu, H.; Cui, G. Novel tetrapeptide, RGDF, mediated tumor specific liposomal doxorubicin (DOX) preparations. Mol. Pharmaceut., 2011, 8, 1224-1232.
100. Wang, Z.; Yu, Y.; Ma, J.; Zhang, H.; Zhang, H.; Wang, X.; Wang, J.; Zhang, X.; Zhang, Q. LyP-1 modification to enhance delivery of artemisinin or fluorescent probe loaded polymeric micelles to highly metastatic tumor and its lymphatics. Mol. Pharmaceut., 2012, 9, 2646-2657.
101. Han, Z.; Fu, A.; Wang, H.; Diaz, R.; Geng, L.; Onishko, H.; Hallahan, D. E. Noninvasive assessment of cancer response to therapy. Nat. Med., 2008, 14, 343-349.
102. Lowery, A.; Onishko, H.; Hallahan, D. E.; Han, Z. Tumor-targeted delivery of liposome-encapsulated doxorubicin by use of a peptide that selectively binds to irradiated tumors. J. Control. Release, 2011, 150, 117-124.
103. Dai, W.; Yang, T.; Wang, Y.; Wang, X.; Wang, J.; Zhang, X.; Zhang, Q. Peptide PHSCNK as an integrin α5β1 antagonist targets stealth liposomes to integrin-overexpressing melanoma. Nanomedicine, 2012, 8, 1152-1161.
104. Khalili, P.; Arakelian, A.; Chen, G.; Plunkett, M. L.; Beck, I.; Parry, G. C.; Doñate, F.; Shaw, D. E.; Mazar, A. P.; Rabbani, S. A. A non-RGD-based integrin binding peptide (ATN-161) blocks breast cancer growth and metastasis in vivo. Mol. Cancer Therap., 2006, 5, 2271-2280.
105. Curnis, F.; Sacchi, A.; Borgna, L.; Magni, F.; Gasparri, A.; Corti, A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol., 2000, 18, 1185-1190.
106. Dickerson, E. B.; Akhtar, N.; Steinberg, H.; Wang, Z.-Y.; Lindstrom, M. J.; Padilla, M. L.; Auerbach, R.; Helfand, S. C. Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin. Mol. Cancer Res., 2004, 2, 663-673.
107. Curnis, F.; Gasparri, A.; Sacchi, A.; Cattaneo, A.; Magni, F.; Corti, A. Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. Cancer Res., 2005, 65, 2906-2913.
108. Cao, Y.; Cao, R.; Veitonmäki, N. Kringle structures and antiangiogenesis. Curr. Med. Chem. Anticancer Agents, 2002, 2, 667-681.
109. Jiang, W.; Jin, G.; Ma, D.; Wang, F.; Fu, T.; Chen, X.; Chen, X.; Jia, K.; Marikar, F. M. M. T.; Hua, Z. Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth. PloS One, 2012, 7, e37132.
110. Marrack, P.; Kappler, J. The staphylococcal enterotoxins and their relatives. Science, 1990, 248, 705-711.
111. Chen, B.; Cao, S.; Zhang, Y.; Wang, X.; Liu, J.; Hui, X.; Wan, Y.; Du, W.; Wang, L.; Wu, K.; Fan, D. A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy. BMC Cell. Biol., 2009, 10, 63.
112. Ellerby, H. M.; Arap, W.; Ellerby, L. M.; Kain, R.; Andrusiak, R.; Rio, G. D.; Krajewski, S.; Lombardo, C. R.; Rao, R.; Ruoslahti, E.; Bredesen, D. E.; Pasqualini, R. Anti-cancer activity of targeted proapoptotic peptides. Nat. Med., 1999, 5, 1032-1038.
113. Smolarczyk, R.; Cichoń, T.; Graja, K.; Hucz, J.; Sochanik, A.; Szala, S. Antitumor effect of RGD-4C-GG-D (KLAKLAK)2 peptide in mouse B16 (F10) melanoma model. Acta Biochim. Polonica, 2006, 53, 801-805.
114. Ma, X.; Xi, L.; Luo, D.; Liu, R.; Li, S.; Liu, Y.; Fan, L.; Ye, S.; Yang, W.; Yang, S.; Meng, L.; Zhou, J.; Wang, S.; Ma, D. Antitumor effects of the peptide TMTP1-GG-D (KLAKLAK) (2) on highly metastatic cancers. PloS One, 2012, 7, e42685.
115. Seo, Y.-W.; Woo, H.-N.; Piya, S.; Moon, A. R.; Oh, J.-W.; Yun, C.-W.; Kim, K.-K.; Min, J.-Y.; Jeong, S.-Y.; Chung, S.; Song, P. I.; Jeong, S.-Y.; Choi, E. K.; Seol, D.-W.; Kim, T.-H. The cell deathinducing activity of the peptide containing Noxa mitochondrialtargeting domain is associated with calcium release. Cancer Res., 2009, 69, 8356-8365.
116. Liu, S.; Yang, H.; Wan, L.; Cai, H.; Li, S.; Li, Y.; Cheng, J.; Lu, X. Enhancement of cytotoxicity of antimicrobial peptide magainin II in tumor cells by bombesin-targeted delivery. Acta Pharmacologica Sinica, 2011, 32, 79-88.
117. Chen, Y.; Xu, X.; Hong, S.; Chen, J.; Liu, N.; Underhill, C. B.; Creswell, K.; Zhang, L. RGD-Tachyplesin inhibits tumor growth. Cancer Res., 2001, 61, 2434-2438.
118. Potala, S.; Verma, R. S. Targeting head and neck squamous cell carcinoma using a novel fusion toxin-diphtheria toxin/HN-1. Mol. Biol. Rep., 2011, 38, 1389-1397.
119. Karmali, P. P.; Kotamraju, V. R.; Kastantin, M.; Black, M.; Missirlis, D.; Tirrell, M.; Ruoslahti, E. Targeting of albuminembedded paclitaxel nanoparticles to tumors. Nanomedicine, 2009, 5, 73-82.
120. Akerman, M. E.; Chan, W. C. W.; Laakkonen, P.; Bhatia, S. N.; Ruoslahti, E. Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci. USA, 2002, 99, 12617-12621.
121. Agemy, L.; Friedmann-Morvinski, D.; Kotamraju, V. R.; Roth, L.; Sugahara, K. N.; Girard, O. M.; Mattrey, R. F.; Verma, I. M.; Ruoslahti, E. Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proc. Natl. Acad. Sci. USA, 2011, 108, 17450-17455.
122. Jiang, X.; Sha, X.; Xin, H.; Chen, L.; Gao, X.; Wang, X.; Law, K.; Gu, J.; Chen, Y.; Jiang, Y.; Ren, X.; Ren, Q.; Fang, X. Selfaggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c (RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors. Biomaterials, 2011, 32, 9457-9469.
123. Jiang, X.; Xin, H.; Gu, J.; Xu, X.; Xia, W.; Chen, S.; Xie, Y.; Chen, L.; Chen, Y.; Sha, X.; Fang, X. Solid tumor penetration by integrinmediated pegylated poly (trimethylene carbonate) nanoparticles loaded with paclitaxel. Biomaterials, 2012, 34, 1739-1746.
124. Zhan, C.; Gu, B.; Xie, C.; Li, J.; Liu, Y.; Lu, W. Cyclic RGD conjugated poly (ethylene glycol)-co-poly (lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J. Control. Release, 2010, 143, 136-142.
125. Hu, Q.; Gu, G.; Liu, Z.; Jiang, M.; Kang, T.; Miao, D.; Tu, Y.; Pang, Z.; Song, Q.; Yao, L.; Xia, H.; Chen, H.; Jiang, X.; Gao, X.; Chen, J. F3 peptide-functionalized PEG-PLA nanoparticles coadministrated with tLyp-1 peptide for anti-glioma drug delivery. Biomaterials, 2012, 34, 1135-1145.
126. Samanta, S.; Sistla, R.; Chaudhuri, A. The use of RGDGWKlipopeptide to selectively deliver genes to mouse tumor vasculature and its complexation with p53 to inhibit tumor growth. Biomaterials, 2010, 31, 1787-1797.
127. Derfus, A. M.; Chen, A. A.; Min, D.-H.; Ruoslahti, E.; Bhatia, S. N. Targeted quantum dot conjugates for siRNA delivery. Bioconjugate Chem., 2007, 18, 1391-1396.
128. Gomes-da-Silva, L. C.; Santos, A. O.; Bimbo, L. M.; Moura, V.; Ramalho, J. S.; Pedroso de Lima, M. C.; Simões, S.; Moreira, J. N. Toward a siRNA-containing nanoparticle targeted to breast cancer cells and the tumor microenvironment. Int. J. Pharm., 2012, 434, 9-19.
129. Numata, K.; Mieszawska-Czajkowska, A. J.; Kvenvold, L. A.; Kaplan, D. L. Silk-based nanocomplexes with tumor-homing peptides for tumor-specific gene delivery. Macromol. Biosci., 2012, 12, 75-82.
130. Numata, K.; Reagan, M. R.; Goldstein, R. H.; Rosenblatt, M.; Kaplan, D. L. Spider silk-based gene carriers for tumor cellspecific delivery. Bioconjugate Chem., 2011, 22, 1605-1610.
131. Fueyo, J.; Gomez-Manzano, C.; Alemany, R.; Lee, P. S.; McDonnell, T. J.; Mitlianga, P.; Shi, Y. X.; Levin, V. A.; Yung, W. K.; Kyritsis, A. P. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene, 2000, 19, 2-12.
132. Jakubczak, J. L.; Ryan, P.; Gorziglia, M.; Clarke, L.; Hawkins, L. K.; Hay, C.; Huang, Y.; Kaloss, M.; Marinov, A.; Phipps, S.; Pinkstaff, A.; Shirley, P.; Skripchenko, Y.; Stewart, D.; Forry-Schaudies, S.; Hallenbeck, P. L. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res., 2003, 63, 1490-1499.
133. Gomez-Manzano, C.; Fueyo, J.; Kyritsis, A. P.; Steck, P. A.; Roth, J. A.; McDonnell, T. J.; Steck, K. D.; Levin, V. A.; Yung, W. K. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res., 1996, 56, 694-699.
134. Jiang, H.; Gomez-Manzano, C.; Lang, F. F.; Alemany, R.; Fueyo, J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr. Gene Ther., 2009, 9, 422-427.
135. Wickham, T. J.; Mathias, P.; Cheresh, D. A.; Nemerow, G. R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell, 1993, 73, 309-319.
136. Fueyo, J.; Alemany, R.; Gomez-Manzano, C.; Fuller, G. N.; Khan, A.; Conrad, C. A.; Liu, T.-J.; Jiang, H.; Lemoine, M. G.; Suzuki, K.; Sawaya, R.; Curiel, D. T.; Yung, W. K. A.; Lang, F. F. Preclinical characterization of the antiglioma activity of a tropismenhanced adenovirus targeted to the retinoblastoma pathway. J. Natl. Cancer Inst., 2003, 95, 652-660.
137. Lang, F. F.; Bruner, J. M.; Fuller, G. N.; Aldape, K.; Prados, M. D.; Chang, S.; Berger, M. S.; McDermott, M. W.; Kunwar, S. M.; Junck, L. R.; Chandler, W.; Zwiebel, J. A.; Kaplan, R. S.; Yung, W. K. A. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol., 2003, 21, 2508-2518.
138. Hajitou, A.; Trepel, M.; Lilley, C. E.; Soghomonyan, S.; Alauddin, M. M.; Marini, F. C.; Restel, B. H.; Ozawa, M. G.; Moya, C. A.; Rangel, R.; Sun, Y.; Zaoui, K.; Schmidt, M.; Von Kalle, C.; Weitzman, M. D.; Gelovani, J. G.; Pasqualini, R.; Arap, W. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell, 2006, 125, 385-398.
139. Tandle, A.; Hanna, E.; Lorang, D.; Hajitou, A.; Moya, C. A.; Pasqualini, R.; Arap, W.; Adem, A.; Starker, E.; Hewitt, S.; Libutti, S. K. Tumor vasculature-targeted delivery of tumor necrosis factoralpha. Cancer, 2009, 115, 128-139.
140. Essler, M.; Gärtner, F. C.; Neff, F.; Blechert, B.; Senekowitsch-Schmidtke, R.; Bruchertseifer, F.; Morgenstern, A.; Seidl, C. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bilabelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis. Eur. J. Nucl. Med. Mol. Imaging, 2012, 39, 602-612.
141. Wang, R. E.; Niu, Y.; Wu, H.; Amin, M. N.; Cai, J. Development of NGR peptide-based agents for tumor imaging. Am. J. Nucl. Med. Mol. Imaging, 2011, 1, 36-46.
142. Zhou, Y.; Chakraborty, S.; Liu, S. Radiolabeled Cyclic RGD Peptides as Radiotracers for Imaging Tumors and Thrombosis by SPECT. Theranostics, 2011, 1, 58-82.
143. Haubner, R.; Wester, H. J.; Burkhart, F.; Senekowitsch-Schmidtke, R.; Weber, W.; Goodman, S. L.; Kessler, H.; Schwaiger, M. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med., 2001, 42, 326-336.
144. Haubner, R.; Wester, H. J.; Weber, W. A.; Mang, C.; Ziegler, S. I.; Goodman, S. L.; Senekowitsch-Schmidtke, R.; Kessler, H.; Schwaiger, M. Noninvasive imaging of alpha (v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res., 2001, 61, 1781-1785.
145. Kenny, L. M.; Coombes, R. C.; Oulie, I.; Contractor, K. B.; Miller, M.; Spinks, T. J.; McParland, B.; Cohen, P. S.; Hui, A.-M.; Palmieri, C.; Osman, S.; Glaser, M.; Turton, D.; Al-Nahhas, A.; Aboagye, E. O. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J. Nucl. Med., 2008, 49, 879-886.
146. Yan, Y.; Chen, K.; Yang, M.; Sun, X.; Liu, S.; Chen, X. A new 18F-labeled BBN-RGD peptide heterodimer with a symmetric linker for prostate cancer imaging. Amino Acids, 2011, 41, 439-447.
147. Li, Z.-B.; Wu, Z.; Chen, K.; Ryu, E. K.; Chen, X. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J. Nucl. Med., 2008, 49, 453-461. (Pubitemid 351355212)
148. Li, Z.-B.; Wu, Z.; Chen, K.; Chin, F. T.; Chen, X. Click chemistry for (18)F-labeling of RGD peptides and microPET imaging of tumor integrin alphavbeta3 expression. Bioconjugate Chem., 18, 2007, 1987-1994.
149. Chen, K.; Chen, X. Positron Emission Tomography Imaging of Cancer Biology: Current Status and Future Prospects. Semin. Oncol., 2011, 38, 70-86.
150. Chen, X.; Park, R.; Tohme, M.; Shahinian, A. H.; Bading, J. R.; Conti, P. S. MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F-and 64Cu-labeled RGD peptide. Bioconjugate Chem., 2004, 15, 41-49.
151. Chen, K.; Ma, W.; Li, G.; Wang, J.; Yang, W.; Yap, L.-P.; Hughes, L. D.; Park, R.; Conti, P. S. Synthesis and evaluation of 64Culabeled monomeric and dimeric NGR peptides for microPET imaging of CD13 receptor expression. Mol. Pharm., 2013, 10 (1), 417-427.
152. Johanna Haukkala; Iina Laitinen; Pauliina Luoto; Peter Iveson; Ian Wilson; Hege Karlsen; Alan Cuthbertson; Jukka Laine; Pia Leppänen; Ylä-Herttula, S.; Knuuti, J.; Roivainen, A. 68Ga-DOTA-RGD peptide: biodistribution and binding into atherosclerotic plaques in mice. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36, 2058-2067.
153. Kim, J. H.; Lee, J. S.; Kang, K. W.; Lee, H.-Y.; Han, S.-W.; Kim, T.-Y.; Lee, Y.-S.; Jeong, J. M.; Lee, D. S. Whole-body distribution and radiation dosimetry of (68)Ga-NOTA-RGD, a positron emission tomography agent for angiogenesis imaging. Cancer Biother. Radiopharm., 2012, 27, 65-71.
154. Li, Z.-B.; Chen, K.; Chen, X. (68)Ga-labeled multimeric RGD peptides for microPET imaging of integrin alpha (v)beta (3) expression. Eur. J. Nucl. Med. Mol. Imaging, 2008, 35, 1100-1108.
155. Sivolapenko, G. B.; Skarlos, D.; Pectasides, D.; Stathopoulou, E.; Milonakis, A.; Sirmalis, G.; Stuttle, A.; Courtenay-Luck, N. S.; Konstantinides, K.; Epenetos, A. A. Imaging of metastatic melanoma utilising a technetium-99m labelled RGD-containing synthetic peptide. Eur. J. Nucl. Med., 1998, 25, 1383-1389.
156. Hua, J.; Dobrucki, L. W.; Sadeghi, M. M.; Zhang, J.; Bourke, B. N.; Cavaliere, P.; Song, J.; Chow, C.; Jahanshad, N.; Van Royen, N.; Buschmann, I.; Madri, J. A.; Mendizabal, M.; Sinusas, A. J. Noninvasive imaging of angiogenesis with a 99mTc-labeled peptide targeted at alphavbeta3 integrin after murine hindlimb ischemia. Circulation, 2005, 111, 3255-3260.
157. Bhojani, M. S.; Ranga, R.; Luker, G. D.; Rehemtulla, A.; Ross, B. D.; Van Dort, M. E. Synthesis and investigation of a radioiodinated F3 peptide analog as a SPECT tumor imaging radioligand. PloS One, 2011, 6, e22418.
158. Haubner, R.; Weber, W. A.; Beer, A. J.; Vabuliene, E.; Reim, D.; Sarbia, M.; Becker, K.-F.; Goebel, M.; Hein, R.; Wester, H.-J.; Kessler, H.; Schwaiger, M. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med., 2005, 2, e70.
159. Axelsson, R.; Bach-Gansmo, T.; Castell-Conesa, J.; McParland, B. J. An open-label, multicenter, phase 2a study to assess the feasibility of imaging metastases in late-stage cancer patients with the alpha v beta 3-selective angiogenesis imaging agent 99mTc-NC100692. Acta Radiologica, 2010, 51, 40-46.
160. Lempens, E. H. M.; Merkx, M.; Tirrell, M.; Meijer, E. W. Dendrimer display of tumor-homing peptides. Bioconjugate Chem., 2011, 22, 397-405.
161. Luo, H.; Shi, J.; Jin, H.; Fan, D.; Lu, L.; Wang, F.; Zhang, Z. An (125)I-labeled octavalent peptide fluorescent nanoprobe for tumorhoming imaging in vivo. Biomaterials, 2012, 33, 4843-4850.
162. Yu, M. K.; Park, J.; Jon, S. Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy. Theranostics, 2012, 2, 3-44.
163. Cai, W.; Chen, X. Multimodality molecular imaging of tumor angiogenesis. J. Nucl. Med., 2008, 49 Suppl 2, 113S-128S.
164. Hu, G.; Lijowski, M.; Zhang, H.; Partlow, K. C.; Caruthers, S. D.; Kiefer, G.; Gulyas, G.; Athey, P.; Scott, M. J.; Wickline, S. A.; Lanza, G. M. Imaging of Vx-2 rabbit tumors with alpha (nu)beta3-integrin-targeted 111In nanoparticles. Int. J. Cancer, 2007, 120, 1951-1957.
165. Hughes, M. S.; Marsh, J. N.; Zhang, H.; Woodson, A. K.; Allen, J. S.; Lacy, E. K.; Carradine, C.; Lanza, G. M.; Wickline, S. A. Characterization of digital waveforms using thermodynamic analogs: detection of contrast-targeted tissue in vivo. IEEE Trans. Ultrason. Ferroelectr. Freq. Control, 2006, 53, 1609-1616.
166. Liu, Z.; Cai, W.; He, L.; Nakayama, N.; Chen, K.; Sun, X.; Chen, X.; Dai, H. In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat. Nanotechnol., 2007, 2, 47-52.
167. Sipkins, D. A.; Cheresh, D. A.; Kazemi, M. R.; Nevin, L. M.; Bednarski, M. D.; Li, K. C. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat. Med., 1998, 4, 623-626.
168. Zhang, C.; Jugold, M.; Woenne, E. C.; Lammers, T.; Morgenstern, B.; Mueller, M. M.; Zentgraf, H.; Bock, M.; Eisenhut, M.; Semmler, W.; Kiessling, F. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res., 2007, 67, 1555-1562.
169. Thorek, D. L. J.; Chen, A. K.; Czupryna, J.; Tsourkas, A. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann. Biomed. Eng., 2006, 34, 23-38.
170. Lin, R.-Y.; Dayananda, K.; Chen, T.-J.; Chen, C.-Y.; Liu, G.-C.; Lin, K.-L.; Wang, Y.-M. Targeted RGD nanoparticles for highly sensitive in vivo integrin receptor imaging. Contrast Media Mol. Imaging, 2012, 7 (1), 7-18.
171. Kim, Y.-H.; Jeon, J.; Hong, S. H.; Rhim, W.-K.; Lee, Y.-S.; Youn, H.; Chung, J.-K.; Lee, M. C.; Lee, D. S.; Kang, K. W.; Nam, J.-M. Tumor targeting and imaging using cyclic RGD-PEGylated gold nanoparticle probes with directly conjugated iodine-125. Small, 2011, 7, 2052-2060.
172. Oostendorp, M.; Douma, K.; Hackeng, T. M.; Dirksen, A.; Post, M. J.; Van Zandvoort, M. A. M. J.; Backes, W. H. Quantitative molecular magnetic resonance imaging of tumor angiogenesis using cNGR-labeled paramagnetic quantum dots. Cancer Res., 2008, 68, 7676-7683.
173. Mulder, W. J. M.; Castermans, K.; Van Beijnum, J. R.; Oude Egbrink, M. G. A.; Chin, P. T. K.; Fayad, Z. A.; Löwik, C. W. G. M.; Kaijzel, E. L.; Que, I.; Storm, G.; Strijkers, G. J.; Griffioen, A. W.; Nicolay, K. Molecular imaging of tumor angiogenesis using alphavbeta3-integrin targeted multimodal quantum dots. Angiogenesis, 2009, 12, 17-24.
174. Zhang, F.; Huang, X.; Zhu, L.; Guo, N.; Niu, G.; Swierczewska, M.; Lee, S.; Xu, H.; Wang, A. Y.; Mohamedali, K. A.; Rosenblum, M. G.; Lu, G.; Chen, X. Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials, 2012, 33, 5414-5422.
175. Xie, J.; Chen, K.; Lee, H.-Y.; Xu, C.; Hsu, A. R.; Peng, S.; Chen, X.; Sun, S. Ultrasmall c (RGDyK)-coated Fe3O4 nanoparticles and their specific targeting to integrin alpha (v)beta3-rich tumor cells. J. Am. Chem. Soc., 2008, 130, 7542-7543.
176. Shao, Y.-Z.; Liu, L.-Z.; Song, S.; Cao, R.; Liu, H.; Cui, C.; Li, X.; Bie, M.-J.; Li, L. A novel one-step synthesis of Gd3+-incorporated mesoporous SiO2 nanoparticles for use as an efficient MRI contrast agent. Contrast Media Mol. Imaging, 6, 110-118.
177. Ye, Y.; Chen, X. Integrin targeting for tumor optical imaging. Theranostics, 2011, 1, 102-126.
178. Cai, W.; Shin, D.-W.; Chen, K.; Gheysens, O.; Cao, Q.; Wang, S. X.; Gambhir, S. S.; Chen, X. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett., 2006, 6, 669-676.
179. Gao, J.; Chen, K.; Xie, R.; Xie, J.; Yan, Y.; Cheng, Z.; Peng, X.; Chen, X. In vivo tumor-targeted fluorescence imaging using nearinfrared non-cadmium quantum dots. Bioconjugate Chem., 2010, 21, 604-609.
180. Chen, X.; Conti, P. S.; Moats, R. A. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res., 2004, 64, 8009-8014.
181. Wang, W.; Ke, S.; Wu, Q.; Charnsangavej, C.; Gurfinkel, M.; Gelovani, J. G.; Abbruzzese, J. L.; Sevick-Muraca, E. M.; Li, C. Near-infrared optical imaging of integrin alphavbeta3 in human tumor xenografts. Mol. Imaging, 2004, 3, 343-351.
182. Cheng, Z.; Wu, Y.; Xiong, Z.; Gambhir, S. S.; Chen, X. Nearinfrared fluorescent RGD peptides for optical imaging of integrin alphavbeta3 expression in living mice. Bioconjugate Chem., 2005, 16, 1433-1441.
183. Hsu, A. R.; Hou, L. C.; Veeravagu, A.; Greve, J. M.; Vogel, H.; Tse, V.; Chen, X. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. Mol. Imaging Biol., 2006, 8, 315-323.
184. Jin, Z.-H.; Josserand, V.; Razkin, J.; Garanger, E.; Boturyn, D.; Favrot, M.-C.; Dumy, P.; Coll, J.-L. Noninvasive optical imaging of ovarian metastases using Cy5-labeled RAFT-c (-RGDfK-)4. Mol. Imaging, 2006, 5, 188-197.
185. Garanger, E.; Boturyn, D.; Coll, J.-L.; Favrot, M.-C.; Dumy, P. Multivalent RGD synthetic peptides as potent alphaVbeta3 integrin ligands. Org. Biomol. Chem., 2006, 4, 1958-1965.
186. Torres Martin de Rosales, R.; Tavaré, R.; Paul, R. L.; Jauregui-Osoro, M.; Protti, A.; Glaria, A.; Varma, G.; Szanda, I.; Blower, P. J. Synthesis of 64Cu (II)-bis (dithiocarbamatebisphosphonate) and its conjugation with superparamagnetic iron oxide nanoparticles: in vivo evaluation as dual-modality PET-MRI agent. Angewandte Chemie, 2011, 50, 5509-5513.
187. Yang, X.; Hong, H.; Grailer, J. J.; Rowland, I. J.; Javadi, A.; Hurley, S. A.; Xiao, Y.; Yang, Y.; Zhang, Y.; Nickles, R. J.; Cai, W.; Steeber, D. A.; Gong, S. cRGD-functionalized, DOXconjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials, 2011, 32, 4151-4160.
188. Glaus, C.; Rossin, R.; Welch, M. J.; Bao, G. In vivo evaluation of (64)Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent. Bioconjugate Chem., 2010, 21, 715-722.
189. Lee, H.-Y.; Li, Z.; Chen, K.; Hsu, A. R.; Xu, C.; Xie, J.; Sun, S.; Chen, X. PET/MRI dual-modality tumor imaging using arginineglycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J. Nucl. Med., 2008, 49, 1371-1379.
190. Li, C.; Wang, W.; Wu, Q.; Ke, S.; Houston, J.; Sevick-Muraca, E.; Dong, L.; Chow, D.; Charnsangavej, C.; Gelovani, J. G. Dual optical and nuclear imaging in human melanoma xenografts using a single targeted imaging probe. Nucl. Med. Biol., 2006, 33, 349-358.
191. Edwards, W. B.; Akers, W. J.; Ye, Y.; Cheney, P. P.; Bloch, S.; Xu, B.; Laforest, R.; Achilefu, S. Multimodal imaging of integrin receptor-positive tumors by bioluminescence, fluorescence, gamma scintigraphy, and single-photon emission computed tomography using a cyclic RGD peptide labeled with a near-infrared fluorescent dye and a radionuclide. Mol. Imaging, 2009, 8, 101-110.
192. Cai, W.; Chen, K.; Li, Z.-B.; Gambhir, S. S.; Chen, X. Dualfunction probe for PET and near-infrared fluorescence imaging of tumor vasculature. J. Nucl. Med., 2007, 48, 1862-1870.
193. Chen, K.; Xie, J.; Xu, H.; Behera, D.; Michalski, M. H.; Biswal, S.; Wang, A.; Chen, X. Triblock copolymer coated iron oxide nanoparticle conjugate for tumor integrin targeting. Biomaterials, 2009, 30, 6912-6919.
194. Jarzyna, P. A.; Deddens, L. H.; Kann, B. H.; Ramachandran, S.; Calcagno, C.; Chen, W.; Gianella, A.; Dijkhuizen, R. M.; Griffioen, A. W.; Fayad, Z. A.; Mulder, W. J. M. Tumor angiogenesis phenotyping by nanoparticle-facilitated magnetic resonance and near-infrared fluorescence molecular imaging. Neoplasia, 2012, 14, 964-973.
195. Kim, K.; Kim, J. H.; Park, H.; Kim, Y.-S.; Park, K.; Nam, H.; Lee, S.; Park, J. H.; Park, R.-W.; Kim, I.-S.; Choi, K.; Kim, S. Y.; Park, K.; Kwon, I. C. Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring. J. Control. Release, 2010, 146, 219-227.
196. Xiao, Y.; Hong, H.; Matson, V. Z.; Javadi, A.; Xu, W.; Yang, Y.; Zhang, Y.; Engle, J. W.; Nickles, R. J.; Cai, W.; Steeber, D. A.; Gong, S. Gold Nanorods Conjugated with Doxorubicin and cRGD for Combined Anticancer Drug Delivery and PET Imaging. Theranostics, 2012, 2, 757-768.
197. Xiao, Y.; Hong, H.; Javadi, A.; Engle, J. W.; Xu, W.; Yang, Y.; Zhang, Y.; Barnhart, T. E.; Cai, W.; Gong, S. Multifunctional unimolecular micelles for cancer-targeted drug delivery and positron emission tomography imaging. Biomaterials, 2012, 33, 3071-3082.
198. Krag, D. N.; Shukla, G. S.; Shen, G.-P.; Pero, S.; Ashikaga, T.; Fuller, S.; Weaver, D. L.; Burdette-Radoux, S.; Thomas, C. Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Res., 2006, 66, 7724-7733. (Pubitemid 44289232)
199. Kapoor, P.; Singh, H.; Gautam, A.; Chaudhary, K.; Kumar, R.; Raghava, G. P. S. TumorHoPe: a database of tumor homing peptides. PloS One, 2012, 7, e35187.
200. Zanuy, D.; Sayago, F. J.; Revilla-López, G.; Ballano, G.; Agemy, L.; Kotamraju, V. R.; Jiménez, A. I.; Cativiela, C.; Nussinov, R.; Sawvel, A. M.; Stucky, G.; Ruoslahti, E.; Alemán, C. Engineering strategy to improve peptide analogs: from structure-based computational design to tumor homing. J. Comput. Aided Mol. Des.i 2013, 27 (1), 31-43.
201. Sharma, A.; Kapoor, P.; Gautam, A.; Chaudhary, K.; Kumar, R.; Chauhan, J. S.; Tyagi, A.; Raghava, G. P. S. Computational approach for designing tumor homing peptides. Scientific Rep., 2013, 3, 1607.
202. Lata, S.; Bhasin, M.; Raghava, G. P. S. MHCBN 4.0: A database of MHC/TAP binding peptides and T-cell epitopes. BMC Res. Notes, 2009, 2, 61.
203. Ansari, H. R.; Flower, D. R.; Raghava, G. P. S. AntigenDB: an immunoinformatics database of pathogen antigens. Nucleic Acids Res., 2010, 38, D847-D853.
204. Saha, S.; Bhasin, M.; Raghava, G. P. S. Bcipep: a database of Bcell epitopes. BMC Genom., 2005, 6, 79.
205. Vita, R.; Zarebski, L.; Greenbaum, J. A.; Emami, H.; Hoof, I.; Salimi, N.; Damle, R.; Sette, A.; Peters, B. The immune epitope database 2.0. Nucleic Acids Res., 2010, 38, D854-D862.
206. Singh, H.; Raghava, G. P. S. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics, 2003, 19, 1009-1014.
207. Saha, S.; Raghava, G. P. S. Prediction methods for B-cell epitopes. Methods Mol. Biol., 2007, 409, 387-394.
208. Ansari, H. R.; Raghava, G. P. Identification of conformational Bcell Epitopes in an antigen from its primary sequence. Immunome Res., 2010, 6, 6.
209. Larsen, J. E. P.; Lund, O.; Nielsen, M. Improved method for predicting linear B-cell epitopes. Immunome Res., 2006, 2, 2.
210. Stranzl, T.; Larsen, M. V.; Lundegaard, C.; Nielsen, M. NetCTLpan: pan-specific MHC class I pathway epitope predictions. Immunogenetics, 2010, 62, 357-368.
211. Lata, S.; Bhasin, M.; Raghava, G. P. S. Application of machine learning techniques in predicting MHC binders. Methods Mol. Biol., 2007, 409, 201-215.
212. Singh, H.; Raghava, G. P. ProPred: prediction of HLA-DR binding sites. Bioinformatics, 2001, 17, 1236-1237.
213. Gautam, A.; Singh, H.; Tyagi, A.; Chaudhary, K.; Kumar, R.; Kapoor, P.; Raghava, G. P. S. CPPsite: a curated database of cell penetrating peptides. Database (Oxford), 2012, 2012, bas015.
214. Sanders, W. S.; Johnston, C. I.; Bridges, S. M.; Burgess, S. C.; Willeford, K. O. Prediction of cell penetrating peptides by support vector machines. PLoS Comput. Biol., 2011, 7, e1002101.
215. Gautam, A.; Chaudhary, K.; Kumar, R.; Sharma, A.; Kapoor, P.; Tyagi, A.; Raghava, G. P. S. In silico approaches for designing highly effective cell penetrating peptides. J. Transl. Med., 2013, 11, 74.
216. Liu, T.; Zhang, J.; Wang, X.; Yang, J.; Tang, Z.; Lu, J. Radiolabeled glucose derivatives for tumor imaging using SPECT and PET. Curr. Med. Chem., 2014, 21 (1), 24-34.